JMP Securities Boosts argenx SE – American Depositary Shares (ARGX) Price Target to $87.00

argenx SE – American Depositary Shares (NASDAQ:ARGX) had its price objective boosted by research analysts at JMP Securities from $74.00 to $87.00 in a research note issued to investors on Monday. The brokerage presently has an “outperform” rating on the stock. JMP Securities’ price objective points to a potential upside of 8.22% from the company’s previous close.

ARGX has been the topic of a number of other reports. Wedbush reaffirmed an “outperform” rating and issued a $41.00 target price (up from $26.00) on shares of argenx SE – American Depositary Shares in a report on Thursday, November 16th. They noted that the move was a valuation call. Zacks Investment Research cut shares of argenx SE – American Depositary Shares from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Finally, Piper Jaffray Companies lifted their target price on shares of argenx SE – American Depositary Shares to $100.00 and gave the company an “overweight” rating in a report on Tuesday, December 19th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. argenx SE – American Depositary Shares currently has an average rating of “Buy” and a consensus price target of $76.25.

Shares of argenx SE – American Depositary Shares (NASDAQ ARGX) traded up $4.97 during trading on Monday, hitting $80.39. 86,319 shares of the stock were exchanged, compared to its average volume of 352,774. argenx SE – American Depositary Shares has a fifty-two week low of $17.33 and a fifty-two week high of $80.58.

A number of large investors have recently bought and sold shares of the stock. Alyeska Investment Group L.P. grew its position in argenx SE – American Depositary Shares by 1.8% in the 3rd quarter. Alyeska Investment Group L.P. now owns 121,313 shares of the company’s stock valued at $2,743,000 after buying an additional 2,167 shares during the last quarter. Artal Group S.A. purchased a new position in argenx SE – American Depositary Shares in the 3rd quarter valued at $1,229,000. Pictet Asset Management Ltd. purchased a new position in argenx SE – American Depositary Shares in the 3rd quarter valued at $11,812,000. AWM Investment Company Inc. purchased a new position in argenx SE – American Depositary Shares in the 2nd quarter valued at $2,121,000. Finally, DAFNA Capital Management LLC purchased a new stake in shares of argenx SE – American Depositary Shares during the 2nd quarter worth $848,000. Hedge funds and other institutional investors own 21.60% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “JMP Securities Boosts argenx SE – American Depositary Shares (ARGX) Price Target to $87.00” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/29/jmp-securities-boosts-argenx-se-american-depositary-shares-argx-price-target-to-87-00.html.

argenx SE – American Depositary Shares Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Receive News & Ratings for argenx SE - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx SE - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply